1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Molecular Diagnostics and NAT Market Size Growth Rate by Type: 2017 VS 2022 VS 2030
1.2.2 Amplification Technologies
1.2.3 Amplified Gene Detection Technologies
1.2.4 DNA And Oligonucleotide Microarrays
1.2.5 Gene Sequencing
1.3 Market by Application
1.3.1 Global Molecular Diagnostics and NAT Market Share by Application: 2017 VS 2022 VS 2030
1.3.2 Hospitals and Clinics
1.3.3 Research Institutes
1.3.4 Diagnostic Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Molecular Diagnostics and NAT Market Perspective (2017-2030)
2.2 Molecular Diagnostics and NAT Growth Trends by Region
2.2.1 Molecular Diagnostics and NAT Market Size by Region: 2017 VS 2022 VS 2030
2.2.2 Molecular Diagnostics and NAT Historic Market Size by Region (2017-2023)
2.2.3 Molecular Diagnostics and NAT Forecasted Market Size by Region (2023-2030)
2.3 Molecular Diagnostics and NAT Market Dynamics
2.3.1 Molecular Diagnostics and NAT Industry Trends
2.3.2 Molecular Diagnostics and NAT Market Drivers
2.3.3 Molecular Diagnostics and NAT Market Challenges
2.3.4 Molecular Diagnostics and NAT Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Molecular Diagnostics and NAT Players by Revenue
3.1.1 Global Top Molecular Diagnostics and NAT Players by Revenue (2017-2023)
3.1.2 Global Molecular Diagnostics and NAT Revenue Market Share by Players (2017-2023)
3.2 Global Molecular Diagnostics and NAT Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Molecular Diagnostics and NAT Revenue
3.4 Global Molecular Diagnostics and NAT Market Concentration Ratio
3.4.1 Global Molecular Diagnostics and NAT Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Molecular Diagnostics and NAT Revenue in 2022
3.5 Molecular Diagnostics and NAT Key Players Head office and Area Served
3.6 Key Players Molecular Diagnostics and NAT Product Solution and Service
3.7 Date of Enter into Molecular Diagnostics and NAT Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Molecular Diagnostics and NAT Breakdown Data by Type
4.1 Global Molecular Diagnostics and NAT Historic Market Size by Type (2017-2023)
4.2 Global Molecular Diagnostics and NAT Forecasted Market Size by Type (2023-2030)
5 Molecular Diagnostics and NAT Breakdown Data by Application
5.1 Global Molecular Diagnostics and NAT Historic Market Size by Application (2017-2023)
5.2 Global Molecular Diagnostics and NAT Forecasted Market Size by Application (2023-2030)
6 North America
6.1 North America Molecular Diagnostics and NAT Market Size (2017-2030)
6.2 North America Molecular Diagnostics and NAT Market Size by Country (2017-2023)
6.3 North America Molecular Diagnostics and NAT Market Size by Country (2023-2030)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Molecular Diagnostics and NAT Market Size (2017-2030)
7.2 Europe Molecular Diagnostics and NAT Market Size by Country (2017-2023)
7.3 Europe Molecular Diagnostics and NAT Market Size by Country (2023-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Molecular Diagnostics and NAT Market Size (2017-2030)
8.2 Asia-Pacific Molecular Diagnostics and NAT Market Size by Country (2017-2023)
8.3 Asia-Pacific Molecular Diagnostics and NAT Market Size by Country (2023-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Molecular Diagnostics and NAT Market Size (2017-2030)
9.2 Latin America Molecular Diagnostics and NAT Market Size by Country (2017-2023)
9.3 Latin America Molecular Diagnostics and NAT Market Size by Country (2023-2030)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Molecular Diagnostics and NAT Market Size (2017-2030)
10.2 Middle East & Africa Molecular Diagnostics and NAT Market Size by Country (2017-2023)
10.3 Middle East & Africa Molecular Diagnostics and NAT Market Size by Country (2023-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Molecular Diagnostics and NAT Introduction
11.1.4 Roche Revenue in Molecular Diagnostics and NAT Business (2017-2023)
11.1.5 Roche Recent Development
11.2 Abbott
11.2.1 Abbott Company Detail
11.2.2 Abbott Business Overview
11.2.3 Abbott Molecular Diagnostics and NAT Introduction
11.2.4 Abbott Revenue in Molecular Diagnostics and NAT Business (2017-2023)
11.2.5 Abbott Recent Development
11.3 BD
11.3.1 BD Company Detail
11.3.2 BD Business Overview
11.3.3 BD Molecular Diagnostics and NAT Introduction
11.3.4 BD Revenue in Molecular Diagnostics and NAT Business (2017-2023)
11.3.5 BD Recent Development
11.4 Biomerieux
11.4.1 Biomerieux Company Detail
11.4.2 Biomerieux Business Overview
11.4.3 Biomerieux Molecular Diagnostics and NAT Introduction
11.4.4 Biomerieux Revenue in Molecular Diagnostics and NAT Business (2017-2023)
11.4.5 Biomerieux Recent Development
11.5 Qiagen
11.5.1 Qiagen Company Detail
11.5.2 Qiagen Business Overview
11.5.3 Qiagen Molecular Diagnostics and NAT Introduction
11.5.4 Qiagen Revenue in Molecular Diagnostics and NAT Business (2017-2023)
11.5.5 Qiagen Recent Development
11.6 Thermo Fisher Scientific
11.6.1 Thermo Fisher Scientific Company Detail
11.6.2 Thermo Fisher Scientific Business Overview
11.6.3 Thermo Fisher Scientific Molecular Diagnostics and NAT Introduction
11.6.4 Thermo Fisher Scientific Revenue in Molecular Diagnostics and NAT Business (2017-2023)
11.6.5 Thermo Fisher Scientific Recent Development
11.7 Agilent
11.7.1 Agilent Company Detail
11.7.2 Agilent Business Overview
11.7.3 Agilent Molecular Diagnostics and NAT Introduction
11.7.4 Agilent Revenue in Molecular Diagnostics and NAT Business (2017-2023)
11.7.5 Agilent Recent Development
11.8 GenMark
11.8.1 GenMark Company Detail
11.8.2 GenMark Business Overview
11.8.3 GenMark Molecular Diagnostics and NAT Introduction
11.8.4 GenMark Revenue in Molecular Diagnostics and NAT Business (2017-2023)
11.8.5 GenMark Recent Development
11.9 Siemens Healthcare
11.9.1 Siemens Healthcare Company Detail
11.9.2 Siemens Healthcare Business Overview
11.9.3 Siemens Healthcare Molecular Diagnostics and NAT Introduction
11.9.4 Siemens Healthcare Revenue in Molecular Diagnostics and NAT Business (2017-2023)
11.9.5 Siemens Healthcare Recent Development
11.10 AutoGenomics
11.10.1 AutoGenomics Company Detail
11.10.2 AutoGenomics Business Overview
11.10.3 AutoGenomics Molecular Diagnostics and NAT Introduction
11.10.4 AutoGenomics Revenue in Molecular Diagnostics and NAT Business (2017-2023)
11.10.5 AutoGenomics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
